2025
Genotype-environment-driven dysbiosis in the skin microbiome of ichthyosis
Zhou W, Ring N, Caldwell R, Milstone L, Oh J. Genotype-environment-driven dysbiosis in the skin microbiome of ichthyosis. Journal Of Investigative Dermatology 2025 PMID: 40571157, DOI: 10.1016/j.jid.2025.06.1568.Peer-Reviewed Original ResearchSkin microbiomeMetabolic pathway levelTransepidermal water lossHost covariatesMetabolic potentialMicrobiome featuresPathway levelImpact hostCutaneous microbiomeMicrobiomeGroup of patientsGenotypesComplex interactionsTGM1Environmental factorsRetinoid usePhenotypeWater lossHostIchthyosisClinical treatmentDiseased skinGenotype-relatedDysbiosisSkinPatients with status epilepticus and new‐onset refractory status epilepticus display drastically altered fecal microbiomes compared to chronic epilepsy patients
Steriade C, Thomas S, Xu F, Ahituv A, Hanin A, Pleshkevich M, Hwang S, Ramirez A, Foreman B, Yoo J, Eka O, Kellogg M, Oliger A, Wainwright M, Morales M, Gaspard N, Hirsch L, Devinsky O, Saxena D. Patients with status epilepticus and new‐onset refractory status epilepticus display drastically altered fecal microbiomes compared to chronic epilepsy patients. Epilepsia 2025 PMID: 40387216, DOI: 10.1111/epi.18450.Peer-Reviewed Original ResearchChronic epilepsy patientsSE patientsStatus epilepticusEpilepsy patientsChronic epilepsyPre-existing epilepsyFuture treatment strategiesDisease time pointsInflammatory cytokine levelsFecal microbiomeMicrobiome structureLongitudinal cohort studyMicrobiome featuresCytokine levelsEffective therapyCohort studyTreatment strategiesInflammatory cytokinesSE resolutionInflammatory responseCritical illnessPatientsGut dysbiosisMortality rateClinical treatmentSelf and Object Representations in Eating Disorders: Combining Research and Psychological Treatment
Bers S. Self and Object Representations in Eating Disorders: Combining Research and Psychological Treatment. Psychoanalytic Inquiry 2025, 45: 90-104. DOI: 10.1080/07351690.2025.2451022.Peer-Reviewed Original ResearchEating-disordered patientsObject representationsPsychological treatmentPatient's inner worldAnorexia nervosa patientsSense of selfWorld of selfEating DisordersSidney BlattYoung adultsInner worldSelfPsychotherapyBlattPsychologyPublished researchInfluence of researchDisordersResearch reportsClinical treatmentSymptomsResearchAdultsTreatmentRepresentation
2024
Multiscale Neuroimaging Features for the Identification of Medication Class and Non-Responders in Mood Disorder Treatment
Baker B, Salman M, Fu Z, Iraji A, Osuch E, Bockholt H, Calhoun V. Multiscale Neuroimaging Features for the Identification of Medication Class and Non-Responders in Mood Disorder Treatment. 2024, 00: 1-5. DOI: 10.1109/isbi56570.2024.10635741.Peer-Reviewed Original ResearchTreatment of mood disordersMood disordersCourse of antidepressantsFunctional network connectivity measuresMedication classesMood disorder treatmentNeuroimaging featuresComplex behavioral symptomsNetwork connectivity measuresMood stabilizersNon-respondersBehavioral symptomsDisorder treatmentNeuroimaging scansResting state functional networksNeural featuresConnectivity measuresFunctional networksMoodDisordersEffective courseAntidepressantsClinical decision supportClinical treatmentSymptomsPartial Hepatectomy and Ablation for Survival of Early-Stage Hepatocellular Carcinoma Patients: A Bayesian Emulation Analysis
Wang J, Im Y, Wang R, Ma S. Partial Hepatectomy and Ablation for Survival of Early-Stage Hepatocellular Carcinoma Patients: A Bayesian Emulation Analysis. Life 2024, 14: 661. PMID: 38929645, PMCID: PMC11204969, DOI: 10.3390/life14060661.Peer-Reviewed Original ResearchOverall survivalHepatocellular carcinomaPartial hepatectomyTumor sizeAssociated with inferior overall survivalEarly-stage hepatocellular carcinomaEarly-stage HCC patientsInferior overall survivalHepatocellular carcinoma patientsAblation armCarcinoma patientsAblation therapyNo significant differenceTreatment regimensHCC patientsEmulated target trialSurgical proceduresEffect of ablationHepatectomyPatientsCompare treatment effectsClinical treatmentSignificant differencePropensity scoreLogistic regressionAn overview of preclinical models of traumatic brain injury (TBI): relevance to pathophysiological mechanisms
Fesharaki-Zadeh A, Datta D. An overview of preclinical models of traumatic brain injury (TBI): relevance to pathophysiological mechanisms. Frontiers In Cellular Neuroscience 2024, 18: 1371213. PMID: 38682091, PMCID: PMC11045909, DOI: 10.3389/fncel.2024.1371213.Peer-Reviewed Original ResearchClosed-Head Impact Model of Engineered Rotational AccelerationModel of traumatic brain injuryPreclinical modelsPreclinical models of traumatic brain injuryAnimal modelsTraumatic brain injuryControlled cortical impact injuryRodent preclinical modelsDisease modifying effectFluid percussion injuryCortical impact injuryBlast injuryAnimal models of traumatic brain injuryBrain injuryMotor vehicle accidentsTherapeutic regimenPathophysiological mechanismsEtiology of traumatic brain injuryPharmacological agentsSports related injuriesInjury modelCalcium dysregulationPrevalence of traumatic brain injuryClinical treatmentClinical setting
2023
Navigating the Complexities of Traumatic Encephalopathy Syndrome (TES): Current State and Future Challenges
Fesharaki-Zadeh A. Navigating the Complexities of Traumatic Encephalopathy Syndrome (TES): Current State and Future Challenges. Biomedicines 2023, 11: 3158. PMID: 38137378, PMCID: PMC10740836, DOI: 10.3390/biomedicines11123158.Peer-Reviewed Original ResearchTraumatic encephalopathy syndromeChronic traumatic encephalopathyTraumatic brain injuryRepetitive head impactsEncephalopathy syndromeHeterogeneity of TBIUnique neurodegenerative diseaseEffective clinical treatmentClinical research studiesEarly diagnostic methodsClinical featuresClinical manifestationsTraumatic encephalopathyRange of treatmentsBrain injuryNeuroimaging markerClinical identificationNeurodegenerative conditionsAlzheimer's diseaseClinical treatmentClinical settingClinical researchNeurodegenerative diseasesNeuropathological phenomenaDiseaseThe future of evolutionary medicine: sparking innovation in biomedicine and public health
Natterson-Horowitz B, Aktipis A, Fox M, Gluckman P, Low F, Mace R, Read A, Turner P, Blumstein D. The future of evolutionary medicine: sparking innovation in biomedicine and public health. Frontiers In Science 2023, 1: 997136. PMID: 37869257, PMCID: PMC10590274, DOI: 10.3389/fsci.2023.997136.Peer-Reviewed Original ResearchEvolutionary dynamicsDevelopment of treatment resistanceLife-history evolutionEvolutionary medicineAnimal model systemsTreatment resistanceAntimicrobial resistancePublic healthTherapeutic approachesHuman pathologiesClinical treatmentReproductive healthDisease burdenPatterns of disease burdenEvolutionary principlesClinical careEcologyModel systemDiseaseDisease vulnerabilityBiomedical researchDisease prevention
2021
Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders
Hecking J, Davoudian PA, Wilkinson ST. Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders. Chronic Stress 2021, 5: 24705470211020446. PMID: 34124495, PMCID: PMC8175843, DOI: 10.1177/24705470211020446.Peer-Reviewed Original ResearchMood disordersMonoamine hypothesisPhase III clinical trialsAmino acid neurotransmitter systemsClassical monoamine hypothesisAmino acid neurotransmittersPublic health issueClinical trialsNovel therapiesNeurotransmitter systemsAV-101Clinical treatmentClinical researchHealth issuesDisordersPotential targetPhase IIPharmaceutical pipelineDrugsGanaxoloneZuranoloneEsketamineBrexanoloneRapastinelPathophysiology
2020
Alcohol-Associated Liver Disease
Liu M, Sehrawat T, Szabo G, Shah V. Alcohol-Associated Liver Disease. 2020, 309-324. DOI: 10.1007/978-3-030-51709-0_20.Peer-Reviewed Original ResearchAn Agenda for Addressing Multimorbidity and Racial and Ethnic Disparities in Alzheimer’s Disease and Related Dementia
Quiñones AR, Kaye J, Allore HG, Botoseneanu A, Thielke SM. An Agenda for Addressing Multimorbidity and Racial and Ethnic Disparities in Alzheimer’s Disease and Related Dementia. American Journal Of Alzheimer's Disease & Other Dementias® 2020, 35: 1533317520960874. PMID: 32969234, PMCID: PMC7984095, DOI: 10.1177/1533317520960874.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseEthnic disparitiesMultiple chronic diseasesMultimorbidity combinationsPoor outcomeAdverse outcomesChronic diseasesHigh burdenRelated dementiaClinical treatmentDiseaseADRDU.S. populationDementia researchMultimorbidityOutcomesBurdenRiskBroad effectsPopulationDementiaDisparitiesCareCaregivers
2018
Analysis of treatment pathways for three chronic diseases using OMOP CDM
Zhang X, Wang L, Miao S, Xu H, Yin Y, Zhu Y, Dai Z, Shan T, Jing S, Wang J, Zhang X, Huang Z, Wang Z, Guo J, Liu Y. Analysis of treatment pathways for three chronic diseases using OMOP CDM. Journal Of Medical Systems 2018, 42: 260. PMID: 30421323, PMCID: PMC6244882, DOI: 10.1007/s10916-018-1076-5.Peer-Reviewed Original ResearchConceptsTreatment pathwaysChronic diseasesStudy of drugsClinical data repositoryClinical treatmentDifferent medical institutionsProportion of monotherapyFirst-line medicationMedical institutionsFirst Affiliated HospitalType 2 diabetesNanjing Medical UniversityDifferent treatment pathwaysMost patientsCommon medicationsAffiliated HospitalMedicationsNational guidelinesMedication informationLocal hospitalMedical UniversitySame diseaseDiseasePatientsNew drugsExpanding Brain–Computer Interfaces for Controlling Epilepsy Networks: Novel Thalamic Responsive Neurostimulation in Refractory Epilepsy
Gummadavelli A, Zaveri HP, Spencer DD, Gerrard JL. Expanding Brain–Computer Interfaces for Controlling Epilepsy Networks: Novel Thalamic Responsive Neurostimulation in Refractory Epilepsy. Frontiers In Neuroscience 2018, 12: 474. PMID: 30108472, PMCID: PMC6079216, DOI: 10.3389/fnins.2018.00474.Peer-Reviewed Original ResearchResponsive neurostimulationRefractory epilepsyThalamic nucleiComplex network disorderIntralaminar thalamic nucleiSubcortical brain structuresCortical onsetSeizure controlGeneralized epilepsySeizure networkSeizure onsetEpilepsy networkNeuromodulatory techniquesEpilepsyExcitatory eventsClinical treatmentBrain regionsBrain structuresSeizuresPotential targetIntracranial electroencephalographyNetwork disorderPatientsFeasible targetNeurostimulationAcute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital.
Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. The Journal Of Clinical Psychiatry 2018, 79 PMID: 30063304, PMCID: PMC6296748, DOI: 10.4088/jcp.17m11731.Peer-Reviewed Original ResearchConceptsMood disordersClinical treatmentTreatment-resistant mood disordersResearch protocolLong-term adverse effectsRapid-acting antidepressantsLong-term safetyEmergence of symptomsRemission rateKetamine infusionFourth infusionLabel therapyTerm outcomesAuthors' institutionPsychiatric hospitalTotal infusionPatientsCognitive declineKetamineTotal treatmentInfusionAdverse effectsClinical samplesLong-term basisTreatmentCharacteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case−control study
Shuey MM, Gandelman JS, Chung CP, Nian H, Yu C, Denny JC, Brown NJ. Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case−control study. BMJ Open 2018, 8: e021640. PMID: 29950471, PMCID: PMC6020960, DOI: 10.1136/bmjopen-2018-021640.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAdultAgedAngiotensin Receptor AntagonistsAntihypertensive AgentsBlack or African AmericanBlood PressureCalcium Channel BlockersCase-Control StudiesDiabetes Mellitus, Type 2Electronic Health RecordsFemaleHumansHypertensionLogistic ModelsMaleMiddle AgedMultivariate AnalysisPrevalenceTennesseeWhite PeopleConceptsElectronic health recordsResistant hypertensionBlood pressureChronic kidney disease stage 3Mineralocorticoid receptor antagonist useClinical treatmentDihydropyridine calcium channel blockerAntihypertensive medication classesControlled blood pressureOutpatient blood pressureTotal hypertensive populationAngiotensin receptor blockersTransient ischemic attackDisease stage 3Health recordsMineralocorticoid receptor antagonistsReceptor antagonist useHigh blood pressureIschemic heart diseaseAlpha-2 agonistsBody mass indexCalcium channel blockersAfrican American patientsNumber of patientsType 2 diabetesS106. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital
Wilkinson S, Webler R, Katz R, Toprak M, Ostroff R, Sanacora G. S106. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. Biological Psychiatry 2018, 83: s388. DOI: 10.1016/j.biopsych.2018.02.997.Peer-Reviewed Original Research
2017
Interventions for Perpetration of Intimate Partner Violence
Stover C, Carlson M. Interventions for Perpetration of Intimate Partner Violence. 2017, 1-15. DOI: 10.1002/9781119057574.whbva076.Peer-Reviewed Original ResearchIntimate partner violenceAvailable evidence basePartner violencePosttraumatic stress disorderFamily-focused interventionsSpecific treatmentCo-occurring violenceVeteran populationSpecific subgroupsBatterer intervention programsClinical treatmentAppropriate interventionsArray of interventionsSubstance abuseStress disorderEvidence baseInterventionIntervention programsIPV interventionsIntervention optionsIPV offendersViolenceTreatmentAvailable optionsOffendersCancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress
Swift T, Belser A, Agin-Liebes G, Devenot N, Terrana S, Friedman H, Guss J, Bossis A, Ross S. Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress. Journal Of Humanistic Psychology 2017, 57: 488-519. DOI: 10.1177/0022167817715966.Peer-Reviewed Original ResearchPsilocybin-assisted psychotherapyClose clinical supervisionQuality of lifeLarge magnitude reductionAvailable emotional supportRecent randomizedTreatment of cancerSingle dosePsilocybin therapyDisease progressionCancer recurrenceCancer placesPatient experienceClinical treatmentCancerPsilocybin sessionCancer diagnosisElevated anxietyAdult participantsInterpretative phenomenological analysisDeathTranscribed interviewsDistressing effectsPsychological mechanismsSemistructured interviews
2016
The anti-hyperglycemic efficacy of a lipid-lowering drug Daming capsule and the underlying signaling mechanisms in a rat model of diabetes mellitus
Zhang Y, Li X, Li J, Zhang Q, Chen X, Liu X, Zhang Y, Zhang H, Yang H, Hu Y, Wu X, Li X, Ju J, Yang B. The anti-hyperglycemic efficacy of a lipid-lowering drug Daming capsule and the underlying signaling mechanisms in a rat model of diabetes mellitus. Scientific Reports 2016, 6: 34284. PMID: 27721485, PMCID: PMC5056381, DOI: 10.1038/srep34284.Peer-Reviewed Original ResearchConceptsDaming capsuleGLP-1Diabetes mellitusRat modelDiabetic ratsRat model of diabetes mellitusModel of diabetes mellitusRegulatory pathwaysClinical treatmentLipid-lowering drugsSecretion of GLP-1Expression of TCF7L2DM ratsClinical treatment of diabetesGIP secretionBlood lipidsTreatment of diabetesAnti-hyperglycemic effectBlood glucose homeostasisMetabolic disordersRatsGlucose levelsTherapeutic drugsSignaling pathwayGlucose homeostasis
2015
Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy
Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, Gill M, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, del Amo J, Moreno S, Rodríguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Pérez-Hoyos S, Jarrin I, Guest JL, Monforte A, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernán MA, Systems A. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. International Journal Of Epidemiology 2015, 45: 2038-2049. PMID: 26721599, PMCID: PMC5841611, DOI: 10.1093/ije/dyv295.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyCopies/Antiretroviral Therapy Cohort CollaborationTime-varying covariatesTight control groupAdjusted hazard ratioAntiretroviral therapy regimenAIDS Research NetworkIntegrated Clinical SystemsHIV-CAUSAL CollaborationDeath eventsCohort CollaborationHazard ratioTherapy regimenRandomized trialsInverse probability weightingInclusion criteriaMortality analysisClinical treatmentAIDSTherapyDeath analysisDeathTrialsComparative effects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply